Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥533.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)49.78K
Market Cap
¥6.19B
Enterprise Value¥1.70B
Total Cash (Recent Filing)¥4.79B
Total Debt (Recent Filing)¥25.26M
Price to Earnings (P/E)63.8
Beta0.98
Next Earnings
Dec 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.58%
Share Statistics
EPS (TTM)3.56
Shares Outstanding19,851,380
10 Day Avg. Volume40,820
30 Day Avg. Volume49,776
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3
Revenue Forecast (FY)¥3.60B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and stable assets and equity provide financial resilience through operating volatility. The company should retain flexibility to fund cell-therapy development and services internally, while facing less balance-sheet strain from interest costs or refinancing needs.
Positive Cash GenerationConsistently positive operating cash flow and free cash flow are important strengths for a biotechnology company, where development and service investments can require sustained funding. Continued cash generation supports operational continuity and reduces reliance on external financing.
Healthy Gross MarginA still-healthy gross margin indicates that the company’s cell-based products and related services retain underlying economic value. This provides a foundation for recovering operating leverage if revenue growth stabilizes and cost pressure moderates over the coming quarters.
Bears Say
Profitability DeteriorationThe sharp decline in net margin weakens earnings quality and reduces the profit cushion available to reinvest in regenerative-medicine capabilities. Near-break-even profitability also makes results more sensitive to cost increases, revenue variability, and execution setbacks.
Weakening Operating LeverageFalling operating profitability despite a revenue rebound suggests that incremental sales are currently producing less operating benefit. If this pattern persists, growth may not translate efficiently into earnings, limiting internal funding capacity and weakening returns on the business model.
Volatile Cash ConversionVolatile free cash flow and weaker 2025 operating cash conversion indicate that accounting earnings are not consistently translating into cash. This can constrain investment flexibility and make funding for research, processing, storage, and service expansion less predictable.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥533.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.19B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Dec 10, 2026 which is in 47 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Sep 08, 2026. The company reported ¥5.21 earnings per share for the quarter.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.58%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,851,380 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥5.21 in its last earnings report. Following the earnings report the stock price went down -2.624%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―